Volume 19, Number 1—January 2013
Research
Invasive Pneumococcal Disease after Routine Pneumococcal Conjugate Vaccination in Children, England and Wales
, Mary P.E. Slack, Nick J. Andrews, Pauline A. Waight, Ray Borrow, and Elizabeth Miller
Table 3
Association between infecting pneumococcal serotype group and presence of comorbidity, England and Wales, September 4, 2006–March 31, 2010*
| Serotype group | Comorbidity, no./total (%) | aOR† (95% CI) | p value |
|---|---|---|---|
| All PCV7-IPD cases‡ | 44/248 (17.7) | ||
| 3 extra PCV10 serotypes (1, 5, 7F) |
15/299 (5.0) § |
0.24 (0.13–0.45) against PCV7 |
<0.001 |
| 3 extra PCV13 serotypes (3, 6A, 19A) | 45/336 (13.4)§ | 0.72 (0.46–1.13) against PCV7 | 0.15 |
| 3.58 (1.93–6.66) against PCV10‡ |
<0.001 |
||
| 11 extra PPV23 serotypes | 39/186 (21.0) | 1.23 (0.76–1.99) against PCV7 | 0.40 |
| 6.02 (3.16–11.5) against PCV10 | <0.001 | ||
| 1.68 (1.04–2.71) against PCV13 |
0.033 |
||
| Remaining non-PPV23 serotypes | 38/138 (27.5) | 1.76 (1.07–2.89) against PCV7 | 0.025 |
| 8.57 (4.46–16.5) against PCV10 | <0.001 | ||
| 2.39 (1.46–3.93) against PCV13 | 0.001 | ||
| 1.42 (0.85–2.40) against PPV23 | 0.18 |
*aOR, adjusted odds ration; PCV7, 7-valent pneumococcal conjugate vaccine; PCV10, 10-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PPV23, 23-valent polysaccharide vaccine.
†Odds ratio adjusted for age, vaccination status, and time since PCV7 introduction by using a multinomial logistic regression with serotype group as the outcome.
‡Serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F.
§Comorbidity was lower for each of the 3 extra PCV10 serotypes, 1 (7/129, 5.4%), 5 (1/17, 5.9%), and 7F (7/153, 4.6%), compared with the additional 3 serotypes in PCV13, 3 (13/98, 13.3%), 6A (12/47, 25.5%), and 19A (20/191, 10.5%).